{"prompt": "['MitraClip NT System', 'Clinical Investigation Plan Version: 1.0', 'Abbott', 'Additional MitraClip NT device intervention, including reason for intervention', 'Echocardiographic Endpoints:', 'The following echocardiographic endpoints will be reported at baseline, discharge, 10 days, 30', 'days. Echocardiographic endpoints will be assessed at baseline, discharge, 10 days, 30 days.', 'MR Severity Grade', 'Effective Regurgitant Orifice Area', 'Regurgitant Volume (RV)', 'Regurgitant Fraction (RF)', 'Left Ventricular End Diastolic Volume (LVEDV)', 'Left Ventricular End Systolic Volume (LVESV)', 'Left Ventricular End Diastolic Dimension (LVEDD)', 'Left Ventricular End Systolic Dimension (LVESD)', 'Left Ventricular Ejection Fraction (LVEF)', 'Right Ventricular Systolic Pressure (RVSP)', 'Mitral Valve Area (MVA)', 'Mean Mitral Valve Pressure Gradient (MVG)', 'Systolic Anterior Motion of the mitral valve (present or absent)', 'Forward Stroke Volume (FSV)', 'Cardiac Output (CO)', 'Cardiac Index (CI)', '5.0 SUBJECT SELECTION AND WITHDRAWAL', '5.1 Subject Population', 'This trial will enroll Russian subjects with symptomatic chronic severe DMR and FMR per the MitraClip NT', 'System IFU. Subjects must meet all eligibility criteria and provide written informed consent prior to', 'conducting any investigation-specific procedures not considered standard of care.', '5.2 Subject Screening', '5.2.1 Subject Screening', 'The Principal Investigator at the site is responsible for screening subjects for the MitraClip NT System Russian', 'Trial. All subjects must have a documented in-person consultation with the Cardiothoracic (CT) Surgeon', 'investigator to assess surgical risk. The MitraClip NT implanter (who may also be the Principal Investigator)', 'and a physician trained in echocardiography will also assess suitability of the subject for eligibility in the trial.', 'These assessments combined are referred to as Site Heart Team. Refer below to the Table 1 for', 'responsibilities.', 'Table 1. Responsibilities', 'Role / Specialty', 'Responsibility', 'Interventional Cardiologist', 'Local Site Heart Team Member', 'Page 33 from 61']['MitraClip NT System', 'Clinical Investigation Plan Version: 1.0', 'Abbott', 'Screens potential subjects', 'Performs MitraClip NT procedure*', 'CT Surgeon', 'Local Site Heart Team Member', 'Provides in-person assessment of surgical difficulty', 'Physician trained on Echocardiography', 'Local Site Heart Team Member', 'Evaluates potential subjects for echocardiographic', 'eligibility criteria', 'Participates in the MitraClip NT procedure', 'Perform required analysis of the TEE & TTE to complete', 'the Case Report Form (CRF)', 'Potential patients will be fully informed about the clinical investigation, following the established Informed', 'Consent process (described in [Section 5.2.2]). Once a duly dated and signed Informed Consent form is', 'obtained, the clinical investigation-specific screening procedures may begin.', \"Subjects must be screened for clinical investigation eligibility by a member of the site's clinical investigation\", 'team previously trained to the CIP, and if applicable will be entered into a site-specific screening log.', 'In case the subject does not meet all inclusion criteria or meets any of the exclusion criteria, the subject is', 'considered a screening failure. The Principal Investigator or the delegated clinical investigation personnel', 'will record the screening failure in the hospital records and on a screening log as required.', 'Subject data will be collected following enrollment into the clinical investigation.', '5.2.2 Informed Consent', 'The Investigator or his/her authorized designee (if applicable) will conduct the Informed Consent process, as', \"required by applicable regulations and the center's IRB/EC. This process will include a verbal discussion with\", \"the subject on all aspects of the clinical investigation that are relevant to the subject's decision to participate,\", 'such as details of clinical investigation procedures, anticipated benefits, and potential risks of clinical', 'investigation participation. Subjects must be informed about their right to withdraw from the clinical', 'investigation at any time and for any reason without sanction, penalty or loss of benefits to which the subject', 'is otherwise entitled. Withdrawal from the clinical investigation will not jeopardize their future medical care or', 'relationship with the investigator.', 'During the discussion, the Principal Investigator or his/her authorized designee will avoid any improper', \"influence on the subject and will respect subject's legal rights. Financial incentives will not be given to the\", 'subject. Subjects may be compensated for time and travel directly related to the participation in the clinical', 'investigation. The subject shall be provided with the Informed Consent form written in a language that is', \"understandable to the subject and has been approved by the center's IRB/EC. The subject shall have\", 'adequate time to review, ask questions, and consider participation. The Principal Investigator or his/her', 'authorized designee will make efforts to ensure that the subject understands the information provided. If the', 'subject agrees to participate, the Informed Consent form must be signed and dated by the subject and', 'Page 34 from 61']\n\n###\n\n", "completion": "END"}